Among people with HIV (PWH) on antiretroviral therapy (ART), GLP-1 receptor agonists and dual GIP/GLP-1 agonists demonstrably reduce visceral adiposity, body weight, inflammatory biomarkers, and liver fat in HIV-specific trials. More speculative findings — including possible effects on gut epithelial integrity, immune-cell trafficking, lymphoid pyroptosis, and DNA-methylation aging clocks — remain at conference-abstract or preprint level and lack prospective validation. The HIV-specific pharmacogenomic landscape and drug-drug interactions with ART regimens are also undercharacterized.
The broader significance here is underappreciated. PWH on long-term ART now routinely face accelerated cardiometabolic aging, lipodystrophy, and chronic low-grade inflammation that standard HIV care does not address. GLP-1 agonists, already reshaping cardiovascular and metabolic medicine in the general population, plausibly target several of these HIV-amplified pathways simultaneously — a rare therapeutic overlap. The confirmed cardiometabolic benefits alone justify integration into clinical practice for eligible PWH, particularly given rising obesity and cardiovascular disease burdens in this cohort. However, the tantalizing hypothesis that GLP-1 agonists could shrink the HIV reservoir or slow immunological aging is far from established. This is a review, not primary data, and its strongest claims rest on small, often post-hoc analyses. Clinicians should embrace the metabolic case; researchers should resist overclaiming immunological or anti-aging effects until randomized prospective evidence arrives.